Medicus Pharma Ltd (MDCX) Price & Analysis

Compare

179 Followers

MDCX Stock Chart & Stats

$1.46

-$0.29(-9.70%)

At close: Jan 08 4:00 PM EST

$1.46

-$0.29(-9.70%)

Day’s Range― - ―

52-Week Range$1.38 - $8.94

Previous CloseN/A

Volume5.92K

Average Volume (3M)327.83K

Market Cap

$36.42M

Enterprise Value$41.63M

Total Cash (Recent Filing)$8.66M

Total Debt (Recent Filing)$236.26K

Price to Earnings (P/E)―

Beta1.31

Next Earnings

Mar 30, 2026

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.12

Shares Outstanding25,114,143

10 Day Avg. Volume231,100

30 Day Avg. Volume327,832

Financial Highlights & Ratios

PEG Ratio0.08

Price to Book (P/B)7.46

Price to Sales (P/S)0.00

P/FCF Ratio-2.28

Enterprise Value/Market Cap1.14

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-1.46

Forecast

1Y Price Target

$12.00

Price Target Upside721.92% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-1.02

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

AI CollaborationCollaboration with Reliant AI to evaluate an AI-enabled clinical data analytics platform under a one-year, milestone-based services agreement capped at $200K could provide a capital-efficient way to accelerate Teverelix development and improve trial analytics.

Clinical Trial CatalystCompletion of enrollment in the Phase 2 basal cell carcinoma trial with top-line results expected in 1Q26 represents a clear efficacy catalyst for Teverelix and SkinJect.

Regulatory ProgressSubmission for the Commissioner's Nation Priority Review voucher (CNPV) and FDA alignment on a 505(b)(2) pathway with bioequivalence guidance and device improvement recommendations strengthens the regulatory path for SkinJect and could enhance approval prospects.

Bears Say

Medicus Pharma Ltd News

Medicus Pharma announces clinical data on Teverelix

Medicus Pharma (MDCX) announces that detailed clinical data on Teverelix, its long-acting gonadotropin-releasing hormone antagonist, have been accepted...

4d ago

MDCX

Medicus Pharma enters non-binding LOI with Reliant AI

Medicus Pharma (MDCX) entered into non-binding letter of intent with Reliant AI to collaborate on the development of...

25d ago

MDCX

Medicus Pharma Highlights Positive Teverelix Phase 1 Data and Near-Term SkinJect Milestones

Medicus Pharma Ltd ( ($MDCX) ) has shared an announcement. Medicus Pharma reported Phase 1 data showing that...

3d ago

MDCX

Medicus Pharma Ramps Up Partnering Push as Phase 2 SkinJect Data Nears

Medicus Pharma Ltd ( ($MDCX) ) just unveiled an update. Medicus Pharma will present at Biotech Showcase 2026...

10d ago

MDCX

Medicus Pharma Launches At-the-Market Equity Offering Program

The latest update is out from Medicus Pharma Ltd ( ($MDCX) ). On December 29, 2025, Medicus Pharma...

16d ago

MDCX

Medicus Pharma Taps Reliant AI for Data-Driven Teverelix Clinical Development

Medicus Pharma Ltd ( ($MDCX) ) has shared an update. Medicus Pharma Ltd. has signed a non-binding letter...

24d ago

MDCX

Medicus Pharma Completes Patient Enrollment for Phase 2 BCC Treatment Study

Medicus Pharma Ltd ( ($MDCX) ) just unveiled an update. Medicus Pharma Ltd. has completed enrollment of 90...

1M ago

MDCX

Medicus Pharma completes enrollment of 90 patients for Phase 2 study

Medicus Pharma (MDCX) announced that its Phase 2 clinical study evaluating safety and efficacy of Doxorubicin Microneedle Array...

1M ago

MDCX

Medicus Pharma’s Warrant Inducement Agreement Announced

Medicus Pharma Ltd ( ($MDCX) ) has issued an announcement. On December 5, 2025, Medicus Pharma Ltd. entered...

1M ago

MDCX

Medicus Pharma Ltd. Strengthens Leadership and Expands Clinical Trials

Medicus Pharma Ltd ( ($MDCX) ) has provided an announcement. Medicus Pharma Ltd. has appointed Carolyn Bonner as...

2M ago

MDCX

Medicus Pharma appoints Carolyn Bonner as CFO

Medicus Pharma (MDCX) announced that Carolyn Bonner, currently President of the Company, has also been appointed CFO, effective...

2M ago

MDCX

Medicus Pharma explores novel treatment innovations for prostate, skin cancers

The company said, “November is Men’s Health Awareness Month, a time to spotlight the latest medical breakthroughs that...

2M ago

MDCX

Medicus Pharma files to sell 2.68M common shares for holders

The company is not selling any securities under this prospectus and will not receive any of the proceeds...

2M ago

MDCX

Is MDCX a Buy, Before Earnings?

Medicus Pharma Ltd (MDCX) is scheduled to report 3rd quarter earnings on 11/21/2025. Regarding Q3 estimates, Wall Street...

2M ago

MDCX

MDCX FAQ

What was Medicus Pharma Ltd’s price range in the past 12 months?

Medicus Pharma Ltd lowest stock price was $1.38 and its highest was $8.94 in the past 12 months.

What is Medicus Pharma Ltd’s market cap?

Medicus Pharma Ltd’s market cap is $36.42M.

When is Medicus Pharma Ltd’s upcoming earnings report date?

Medicus Pharma Ltd’s upcoming earnings report date is Mar 30, 2026 which is in 73 days.

How were Medicus Pharma Ltd’s earnings last quarter?

Medicus Pharma Ltd released its earnings results on Nov 21, 2025. The company reported -$1.12 earnings per share for the quarter, missing the consensus estimate of -$0.945 by -$0.175.

Is Medicus Pharma Ltd overvalued?

According to Wall Street analysts Medicus Pharma Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Medicus Pharma Ltd pay dividends?

Medicus Pharma Ltd does not currently pay dividends.

What is Medicus Pharma Ltd’s EPS estimate?

Medicus Pharma Ltd’s EPS estimate is -0.15.

How many shares outstanding does Medicus Pharma Ltd have?

Medicus Pharma Ltd has 25,114,143 shares outstanding.

What happened to Medicus Pharma Ltd’s price movement after its last earnings report?

Medicus Pharma Ltd reported an EPS of -$1.12 in its last earnings report, missing expectations of -$0.945. Following the earnings report the stock price went up 4.412%.

Which hedge fund is a major shareholder of Medicus Pharma Ltd?

Currently, no hedge funds are holding shares in MDCX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Medicus Pharma Ltd Stock Smart Score

Underperform

Fundamentals

Return on Equity

-2237.54%

Trailing 12-Months

Asset Growth

74.41%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Medicus Pharma Ltd

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.

Medicus Pharma Ltd (MDCX) Earnings & Revenues

Historic Earnings Reports

MDCX Stock 12 Month Forecast

Average Price Target

$12.00

▲(721.92% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.98,2.750769230769231,3.5215384615384613,4.292307692307692,5.063076923076923,5.833846153846154,6.604615384615384,7.375384615384615,8.146153846153846,8.916923076923077,9.687692307692307,10.458461538461538,11.22923076923077,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.98,2.750769230769231,3.5215384615384613,4.292307692307692,5.063076923076923,5.833846153846154,6.604615384615384,7.375384615384615,8.146153846153846,8.916923076923077,9.687692307692307,10.458461538461538,11.22923076923077,{"y":12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.98,2.750769230769231,3.5215384615384613,4.292307692307692,5.063076923076923,5.833846153846154,6.604615384615384,7.375384615384615,8.146153846153846,8.916923076923077,9.687692307692307,10.458461538461538,11.22923076923077,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.44,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.56,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.32,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >